Citigroup
BBIO icon

Citigroup’s BridgeBio Pharma BBIO Stock Holding History

Citigroup’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.4M Buy
864,101
+117,618
+16% +$8.24M 0.02% 635
2026
Q1 		$55.4M Buy
746,483
+46,232
+7% +$3.35M 0.02% 602
2025
Q4 		$53.6M Sell
700,251
-227,700
-25% -$14.9M 0.02% 613
2025
Q3 		$48.2M Sell
927,951
-320,554
-26% -$15.6M 0.02% 647
2025
Q2 		$53.9M Sell
1,248,505
-153,008
-11% -$5.57M 0.03% 567
2025
Q1 		$48.5M Sell
1,401,513
-137,219
-9% -$4.63M 0.02% 564
2024
Q4 		$42.2M Buy
1,538,732
+929
+0.1% +$24K 0.03% 596
2024
Q3 		$39.2M Buy
1,537,803
+222,464
+17% +$5.84M 0.02% 634
2024
Q2 		$33.3M Sell
1,315,339
-474,731
-27% -$13M 0.02% 668
2024
Q1 		$55.3M Buy
1,790,070
+232,839
+15% +$7.92M 0.04% 441
2023
Q4 		$62.9M Sell
1,557,231
-30,361
-2% -$912K 0.04% 373
2023
Q3 		$41.9M Buy
1,587,592
+160,076
+11% +$4.54M 0.03% 494
2023
Q2 		$24.6M Sell
1,427,516
-119,529
-8% -$1.8M 0.02% 727
2023
Q1 		$25.7M Buy
1,547,045
+162,116
+12% +$1.89M 0.02% 708
2022
Q4 		$10.6M Sell
1,384,929
-135,132
-9% -$1.29M 0.01% 1107
2022
Q3 		$15.1M Buy
1,520,061
+45,659
+3% +$474K 0.01% 932
2022
Q2 		$13.4M Buy
1,474,402
+343,362
+30% +$2.87M 0.01% 1005
2022
Q1 		$11.5M Sell
1,131,040
-81,298
-7% -$834K 0.01% 1237
2021
Q4 		$20.2M Buy
1,212,338
+735,295
+154% +$31.1M 0.01% 1004
2021
Q3 		$22.4M Sell
477,043
-152,317
-24% -$8.16M 0.01% 931
2021
Q2 		$38.4M Buy
629,360
+25,960
+4% +$1.48M 0.02% 640
2021
Q1 		$37.2M Buy
603,400
+63,047
+12% +$4.12M 0.02% 634
2020
Q4 		$38.4M Sell
540,353
-186,055
-26% -$8.98M 0.02% 680
2020
Q3 		$27.3M Sell
726,408
-84,405
-10% -$2.66M 0.02% 757
2020
Q2 		$26.4M Buy
810,813
+693,775
+593% +$21.1M 0.02% 671
2020
Q1 		$3.39M Buy
117,038
+92,075
+369% +$2.85M ﹤0.01% 2009
2019
Q4 		$874K Buy
24,963
+23,959
+2,386% +$664K ﹤0.01% 3901
2019
Q3 		$21K Buy
+1,004
New +$27.8K ﹤0.01% 6697

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Citigroup's BBIO Position: Q2 2026 in Review

Citigroup increased its BridgeBio Pharma (BBIO) stake by 16% in Q2 2026, buying an estimated $8.24M and bringing the position to 864,101 shares worth $64.4M. The position accounts for 0.02% of the portfolio, ranked #635.

Citigroup first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Citigroup held 864,101 shares of BridgeBio Pharma worth $64.4M as of Q2 2026.
  • Citigroup bought 117,618 BridgeBio Pharma shares in Q2 2026, an estimated $8.24M.
  • BridgeBio Pharma made up 0.02% of Citigroup's portfolio in Q2 2026, its #635 holding.
  • Citigroup first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.